Issue 3.23
As biopharma pipelines transition away from traditional, blockbuster-style products and toward highly targeted, complex modalities, the industry’s approach to investing into bioprocessing is shifting...
As biopharma pipelines transition away from traditional, blockbuster-style products and toward highly targeted, complex modalities, the industry’s approach to investing into bioprocessing is shifting...
Bioprocessing is undergoing a transformation as various technological and process advancements help to improve yields, efficiency, and safety for drug developers and manufacturers...
Peptide therapeutics have the potential to become blockbusters on a scale that was previously seen within the monoclonal antibody space thanks to their effectiveness and biocompatibility...
Oral drug products have helped improve the lives of many patients, offering treatment in a convenient and easy to manage way; however, if the finished drug is unpalatable,…
The biopharmaceutical industry is moving away from the traditional blockbuster drug model, where facilities manufactured vast quantities of a single product, toward more personalized, highly targeted therapies and…
Drug development is shifting away from the traditional, legacy small-molecule pipelines and focusing on increasingly complex products that require greater technical acumen and specialized equipment, reveals Mark DaFonseca,…
The global bio/pharmaceutical outsourcing industry is experiencing a paradigm shift driven by macroeconomic pressures, changing regulatory paradigms, and the rise of asset-light virtual biotechnology firms…
The bio/pharmaceutical industry is in the midst of disruptive evolution thanks to an influx of niche modalities in development pipelines and increasing adoption of innovative, digital technologies that…
The corporate landscape for pharmaceutical networking has traditionally been defined through the exhibition format, with hallways of expansive vendor booths designed primarily for product discovery...
Pharmaceutical excipients are considered an essential part of modern drug formulation. Comprising approximately 50–90% of the finished product, excipients ensure that limitations of the API, such as poor…
Generic and biosimilar drugs are vitally important for healthcare systems around the world and are increasingly in demand from patients thanks to their affordability when compared with the…
As the modern drug development pipeline becomes ever more saturated with complex molecules and targets shift toward ‘undruggable’ protein–protein interfaces, formulators are facing a solubility crisis that traditional…
THE BIG READ
Circio Raises Funds to Advance in vivo CAR-T Program
4 min read • 2 weeks ago
The Norwegian biotech plans to use the raised capital to expand its circular RNA platform and secure complementary vector and delivery technologies for an in vivo CAR-T therapy.
The Lithuanian CDMO has opened a new facility in Vilnius that can support advanced and personalized therapies, including…
By combining Nottingham’s development capabilities with its expanded Haverhill site, Codis creates an integrated UK pathway spanning early-stage…
The biotech, which was formerly known as EG 427, will use the funds raised in its Series C…
THE BIG READ
Nanoform Highlights CESS Benefits Versus Spray-Dried ASDs
4 min read • 1 week ago
According to the company, its commercial-scale nanoparticle manufacturing technology could reduce production costs and solvent use while increasing drug loading.
The company has managed to raise USD 70 million, which it will use to progress its lead candidate…
Through this certified status, the CDMO will be able to offer its customers targeted, multiplex protein biomarker analysis…
Although the trial did not meet its primary endpoint, EyePoint reported a 42% reduction in overall treatment burden,…
THE BIG READ
CPHI Milan 2026: Connecting Supply Chains, Digital Innovations, and Sustainability
4 min read • 4 days ago
Ahead of CPHI Milan, Event Director Tara Dougal shares insights on the key themes, new dedicated zones, and networking opportunities shaping this year’s global biopharmaceutical gathering.
Ahead of CPHI Milan 2026, Professor Hanns-Christian Mahler from ten23 health, explores how expanding dose volumes, flexible CDMO…
As demand for patient-centric chronic disease treatments grows, Nanexa CTO Mårten Rooth discusses how atomic layer deposition enables…
As biopharma moves beyond traditional batch processing, industry leaders evaluate how the FDA’s Advanced Manufacturing Technology designation program…
THE BIG READ
Lifecore Biomedical Signs Major Commercial Site-Transfer Deal
4 min read • 4 days ago
The Minnesota injectables CDMO has signed a technical transfer and manufacturing agreement for a currently marketed, high-viscosity injectable, marking its seventh late‑stage commercial program and 11th pipeline addition…
A global licensing agreement worth up to EUR 1.165 billion will leverage Nanexa's PharmaShell technology to develop long-acting…
The Minnesota injectables CDMO has signed a technical transfer and manufacturing agreement for a currently marketed, high-viscosity injectable,…
Through this acquisition, Eli Lilly will strengthen its immunology capabilities by gaining access to a first-in-class antibody-degradation platform…
THE BIG READ
Roche Gets Nod from European Commission for Susvimo
4 min read • 2 weeks ago
The European Commission has approved the ranibizumab 100 mg/mL injectable solution (Susvimo) from Roche as a treatment of neovascular age-related macular degeneration.
The U.S. regulatory body has approved AstraZeneca’s Etcamah in combination with CDK4/6 inhibitors, to treat adults with HR‑positive,…
A combination therapy from Gilead and Merck has met its clinical efficacy endpoint, demonstrating non-inferiority to existing daily…
AstraZeneca’s camizestrant has faced a regulatory setback in the U.S., with the FDA extending its review, seeking clearer…
THE BIG READ
Codis Appoints Steven Facer in New Role as Chief Commercial Officer
4 min read • 1 week ago
The newly created role will bring the CDMO’s sales, marketing, and business development teams under a unified commercial strategy across the U.S. and UK.
SPONSORED CONTENT: As the biopharmaceutical landscape increasingly demands integrated technical operations, GCCs are expanding beyond back-office efficiency, reveals…
As the divide between upstream output and downstream capability in bioprocessing expands, it is becoming necessary for the…
Experts from Alcami break down the latest innovations in lipid-based permeation matrices, continuous direct compression, and advanced analytical…
BioTechX connects the biotech and pharmaceutical ecosystem across drug discovery, clinical trials, R&D, data science, technology, investment, and pharma.
CPHI Milan brings together a global network of pharmaceutical professionals.
The ISPE Boston Product Show brings the life sciences community together to connect, discover, and move the industry forward.
A Taste of Italy Tour connecting attendees with leading CDMOs at CPHI Milan.